RAC1 and melanoma: Moreover, the combination of a Rac1 inhibitor and vemurafenib (a drug that targets mutant BRAF kinase but lacks long-lasting efficacy because of acquired resistance [30]) suppressed melanoma growth and metastasis to a higher degree than either agent as monotherapy.